Related Experiment Videos
Molecular biology of oncogenes and cardiovascular hypertrophy
Journal of Hypertension
|December 1, 1992
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians.
Journal of molecular medicine (Berlin, Germany)·2001
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment].
Deutsche medizinische Wochenschrift (1946)·2001
Clinical differences between benign and malignant pheochromocytomas.
Endocrine journal·2001
Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2001
Diagnostic recognition of primary aldosteronism in clinical practice.
Journal of hypertension·2026
Marinobufagenin and left ventricular mass and geometry in patients with essential hypertension.
Journal of hypertension·2026
Zerumbone combined with antimicrobial photodynamic inactivation reduces growth of Candida albicans biofilms and modulates virulence gene expression.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Inhibiting glioma cell invasion by sequential photo-sonodynamic therapy.
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Vismodegib-loaded ufasomes inhaler for treatment of non-small cell lung cancer.
Naunyn-Schmiedeberg's archives of pharmacology·2026
A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma.
Journal of medicinal chemistry·2026
Small-Molecule Activators of PRMT1: Discovery, SAR Analyses, and Proapoptotic Effects in Pancreatic Cancer Cells.
Journal of medicinal chemistry·2026
Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.
Journal of medicinal chemistry·2026